Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-like-conjugating enzyme ATG10 (ATG10) is a cytoplasmic protein acting as an E2-like enzyme. It plays a central role in the autophagy pathway by mediating the conjugation of ATG12 to ATG5, an essential step in autophagosome formation and maturation[2][3][4][7]. ATG10 has two isoforms in humans: the canonical long isoform and a shorter isoform (ATG10S), which may exert distinct effects on viral replication and autophagy flux[1]. ATG10 is implicated in neurodegenerative disorders, viral infections (notably hepatitis C), and cancer through its role in cellular degradation processes and cell survival[1][2]. It functions as part of the ubiquitin-like protein conjugation system, distinguishing it from traditional ubiquitin E2 enzymes via unique structural features[3]. ATG10 may serve as a therapeutic target for modulating autophagy in diseases where this process is dysregulated[1][2].
Modulation of autophagy flux (restoration or inhibition); Inhibition or enhancement of ATG12-ATG5 conjugation; Promotion or suppression of autophagosome formation[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-like-conjugating enzyme ATG10 (ATG10).